060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. (12th April 2019) - Smolen, J S; Cohen, S; Emery, P; Rigby, W; Tanaka, Y; Zhang, Y; Friedman, A; Othman, A A; Camp, H S; Pangan, A L